NCT05237206 - Study of SUPLEXA in Patients With Metastatic Solid Tumours and Haematologic Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 28, 2022

Primary Completion Date

July 23, 2024

Study Completion Date

July 23, 2024

Conditions

Oncology

Interventions

BIOLOGICAL

SUPLEXA

PBMC-derived autologous cellular therapy derived through an ex vivo activation procedure, resulting in a cell mixture comprised predominantly of NK, NK-T, and T cells stored in cryogenic media.

Trial Locations (3)

4120

Greenslopes Private Hospital/Gallipoli Medical Research Foundation, Brisbane

5000

Cancer Research Sa (Crsa), Adelaide

5042

Southern Oncology Clinical Research Unit (SOCRU), Adelaide